Journal article
Abstract P171: Potential Mortality Reduction with Optimal Usage of sacubitril/valsartan Therapy for the Treatment of Heart Failure in Canada
Abstract
Background: Despite well-recognized standard of care therapies, heart failure (HF) continues to be characterized by high mortality rates. Sacubitril/valsartan, a first-in-class treatment for HF with reduced ejection fraction (HFrEF) provided incremental cardiovascular and overall survival benefit in PARADIGM-HF, the largest clinical trial ever conducted in HF patients. We hypothesized that optimal use of sacubitril/valsartan in the treatment of …
Authors
McKelvie R; White M; Vaillancourt M; Haddad P; Zaour N
Journal
Circulation, Vol. 135, No. suppl_1,
Publisher
Wolters Kluwer
Publication Date
March 7, 2017
DOI
10.1161/circ.135.suppl_1.p171
ISSN
0009-7322